Good Q1 2025, portfolio review
08/05/25 -"Organic sales growth and operating margin improvement were in line with expectations, with all divisions contributing to the overall performance. At constant currency, sales growth in Technology and ..."
Pages
49
Language
English
Published on
08/05/25
You may also be interested by these reports :
06/02/26
We adopt a more cautious stance on Experian, as AI-related developments drive sector-wide compression across legacy data and analytics companies, ...
04/02/26
Q4 2025 was a solid quarter, with organic growth across all regions driven by price increases in security services and the development of technology ...
29/01/26
Eurofins Scientific’s 2025 results were in line with the Visible Alpha consensus but slightly below our expectations. Organic growth was marginally ...
27/01/26
After the pre-close call for FY25 that we had with management, we again adjust our topline growth forecasts for the group, with an impact on EPS. ...